

P. vivax positive cases
assessed for eligibility
(n=2172)

Excluded (n=1636)
Refusal of consent (n=608)
Prior history of antimalarial use (n=394)
Anticipated difficulty with follow-up (n=337)
Concomitant disease (n=228)
Pregnancy or lactation (n=113)
Mixed infection (n=44)
Signs of severity (n=12)

536 cases randomised

Allocated to CQ (n=268)
Received all CQ doses (n=266)
Did not complete CQ (n=2)

Allocated to DP (n=268)
Received all DP doses (n=265)
Did not complete DP (n=3)

Lost to follow-up before d56 (n=13)

Lost to follow-up before d56 (n=25)

Completed to d56 without failure (n=230)
Failed on or before d56 (n=23)

Completed to d56 without failure (n=233)
Failed on or before d56 (n=7)